Trial Profile
Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Eflornithine/sulindac (Primary) ; Eflornithine; Sulindac
- Indications Familial adenomatous polyposis
- Focus Registrational; Therapeutic Use
- Sponsors Cancer Prevention Pharmaceuticals
- 11 Sep 2020 Results presented in a Cancer Prevention Pharmaceuticals Media Release.
- 10 Sep 2020 Results published in the New England Journal of Medicine
- 29 Jun 2020 According to a Cancer Prevention Pharmaceuticals media release, the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP).